PHI with Ceelen-Gellerstedt syndrome
How does this condition affect your private health insurance?
Ceelen-Gellerstedt-Syndrom, or Idiopathic Pulmonary Hemosiderosis (IPH), is a rare lung disorder characterized by recurrent episodes of diffuse alveolar hemorrhage. This leads to iron accumulation (hemosiderin) in the lungs, manifesting as a triad of hemoptysis, iron-deficiency anemia, and diffuse pulmonary infiltrates. Its etiology is unknown, distinguishing it from secondary hemosiderosis. Primarily affecting children, it causes chronic blood loss into the lungs, potentially resulting in pulmonary fibrosis, respiratory failure, and severe systemic complications, requiring long-term management to prevent irreversible organ damage and maintain quality of life.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Acute episodes can range from a few days to several weeks, often requiring hospitalization for stabilization and treatment.
Duration of Illness (Lifetime)
Typically a chronic disease with recurrent exacerbations throughout a patient's life, requiring ongoing medical management.
Cost of Treatment (Initial)
Can range from $10,000 to $50,000 or more, involving hospitalization, intensive care, diagnostics, blood transfusions, and corticosteroid therapy.
Cost of Treatment (Lifetime)
Hundreds of thousands to potentially millions of dollars, including repeated hospitalizations, continuous immunosuppressive therapy, monitoring, and management of complications like pulmonary fibrosis.
Mortality Rate
Significant, especially in severe acute episodes or poorly managed chronic cases. Mortality rates can be 10-50%, higher in children and if untreated or presenting with massive hemorrhage.
Risk of Secondary Damages
High. Common complications include severe iron-deficiency anemia, progressive pulmonary fibrosis, pulmonary hypertension, growth retardation in children, chronic respiratory insufficiency, and organ damage.
Probability of Full Recovery
Low. While remissions are possible with treatment, complete, permanent recovery without the risk of recurrence or residual lung damage is rare, as it is a chronic, often lifelong condition.
Underlying Disease Risk
Low for direct causative underlying diseases, as IPH is idiopathic by definition. However, other conditions (e.g., autoimmune diseases, vasculitis) must be excluded to confirm the diagnosis of IPH.